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A B S T R A C T
Purpose: This study was intended to document the clinical proﬁle and treatment outcome of West
syndrome in children attending a tertiary care center in Northern India.
Method: Data were collected by a retrospective chart review of children diagnosed with West syndrome
between January 2008 and January 2012. Information was recorded pertaining to the age at onset and
presentation, etiology, and associated co-morbidities; results of electroencephalography (EEG) and
neuroimaging; treatment given; and ﬁnal outcome. The following drugs were used for treatment:
pyridoxine, prednisolone, vigabatrin, sodium valproate, nitrazepam, topiramate, and levetiracetam. The
response was categorized as spasm cessation, partial improvement (>50% improvement), or no
improvement. The ﬁnal outcome was considered favorable when there was a complete cessation of
spasms; with absence of relapse and no progression to other seizure types for at least 6 months.
Results: Records of 148 children (120 boys) were analyzed. The mean (SD) age at onset and presentation
was 5.3 (4.6) months, and 13.1 (7.3) months, respectively. Perinatal asphyxia (61.4%), neonatal sepsis/
meningitis (10.6%), and postnatal meningitis (11.4%) were the predominant causes. The etiology could
not be ascertained in 16.6% of children. Favorable outcome was observed in 45 (30.4%) children with
spasm cessation rate of 25.4% with prednisolone. Age at onset, gender, time lag to treatment, presence of
perinatal asphyxia, or co-morbid cerebral palsy did not affect the ﬁnal outcome.
Conclusion: This study highlights the developing country perspective of children with West syndrome,
including delayed presentation, adverse perinatal events as the predominant etiology, and modest
response to oral steroids.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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West syndrome is an epileptic encephalopathy characterized by
epileptic spasms, electroencephalographic evidence of hypsar-
rhythmia, and developmental delay or regression. The peak age of
onset is 4–7 months.1 The etiology is highly heterogeneous and
includes cortical malformations, neurocutaneous syndromes,
inherited metabolic disorders, perinatal brain injuries (asphyxia,
hypoglycemia, sepsis, and meningitis), and postnatal acquired
brain injuries such as meningitis and head trauma. Based on
etiology, West syndrome is classiﬁed as symptomatic with known
etiology and cryptogenic or (unknown etiology).2 The symptom-
atic group represents 60–80% of cases. West syndrome is a
difﬁcult-to-treat disorder characterized by poor response to
antiepileptic drugs and consequent intellectual disability.
Information on the proﬁle of infants with West syndrome in
developing countries is limited.3–6 Management of children in* Corresponding author. Tel.: +91 9910234344.
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http://dx.doi.org/10.1016/j.seizure.2013.04.014resource-constrained settings is limited by delay in presentation
and high cost of drugs such as adrenocorticotrophic hormone
(ACTH) and vigabatrin. Hence, this retrospective study was
conducted to evaluate the clinical proﬁle and treatment outcome
of children with West syndrome in a developing country scenario.
2. Methodology
This study was conducted at the pediatric department of Lady
Hardinge Medical College and Kalawati Saran Children Hospital, a
tertiary care government-sponsored teaching hospital in New
Delhi, India. The patients seeking treatment in this hospital belong
to Delhi and surrounding rural districts of Haryana, Uttar Pradesh,
and Punjab. These patients predominantly belong to the lower
socioeconomic status and do not have any form of health
insurance.
2.1. Patient selection
Data were collected by a retrospective chart review of all
patients diagnosed with West syndrome between January 2008vier Ltd. All rights reserved.
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Fig. 1. Flow chart of treatment protocol of West syndrome at our center (NR, no
response; PR, partial response).
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for less than 6 months were excluded. The diagnosis of West
syndrome was based on the presence of epileptic spasms, along
with electroencephalographic (EEG) ﬁndings of hypsarrhythmia or
its variants. Hypsarrhythmia was deﬁned as EEG showing high-
voltage chaotic slow waves intermixed with spike and sharp wave
discharges. Modiﬁed hysparrythmia was deﬁned in presence of
any of the following: increased interhemispheric synchronization-
consistent voltage asymmetries; consistent focus of abnormal
discharge; episodes of generalized/regional or lateralized voltage
attenuation; or primarily high-voltage bilaterally asynchronous
slow wave activity.7
2.2. Baseline clinical data
The following data were collected from the case records: sex,
age of onset of infantile spasms, age at diagnosis, and the type of
spasms. The average number of spasms per cluster and number of
clusters per day was recorded. The frequency of spasms was noted
from parent-maintained seizure dairy or parental recall during
visits. History of sleep problems, feeding problems, and presence of
repeated chest infections was also noted. The ‘lag time’ was deﬁned
as the time from initial observation of spasms to diagnosis.
History of perinatal events, developmental milestones and
relevant family events was recorded. The diagnosis of birth
asphyxia was considered when the delayed cry at birth was
followed with features of neonatal encephalopathy. Physical
examination ﬁndings suggestive of cerebral palsy, microcephaly,
presence of neurocutaneous markers, dysmorphism, and organo-
megaly were documented.
2.3. Investigations
The results of EEG and neuroimaging (CT/MRI) were noted.
Computed tomography (CT) scan was the initial investigation in
children where there was a clear history suggestive of perinatal
insult, postnatal meningitis, or encephalitis. Magnetic resonance
imaging (MRI) was performed in all the other cases, and in cases
where the CT scan was normal. Children with clinical suspicion of
metabolic disorders (a history of parental consanguinity, prior
affected siblings, unexplained vomiting, intermittent worsening of
symptoms, recurrent episodes of lethargy, altered sensorium, or
ataxia or hepatosplenomegaly on examination) or no obvious
etiology on clinical evaluation and neuroimaging were screened
for inherited metabolic disorders based on reports of arterial blood
gas, blood lactate, blood ammonia, urine ketones, and blood
tandem mass spectrometry. Based on the etiology, West syndrome
was classiﬁed as symptomatic (known etiology) or cryptogenic
(unknown etiology).
2.4. Treatment protocol
Available treatment options included prednisolone, pyridoxine,
sodium valproate, vigabatrin, nitrazepam, topiramate, and levetir-
acetam. Treatment options varied according to the affordability of
the treatment for the patient and associated infection and
malnutrition. Prednisolone and sodium valproate are available
free from the hospital. The usual protocol at our center is to start
with a trial of pyridoxine (15 mg/kg/day) for 3–7 days (Fig. 1). In
pyridoxine unresponsive patients, oral prednisolone (2 mg/kg/
day) was given. Patients who were severely malnourished or had
evidence of active tuberculosis were not administered steroids.
These patients were treated with vigabatrin. Those who failed
steroids were also started on vigabatrin if the parents could afford
it. Otherwise, the treatment options included sequential trials of
sodium valproate, nitrazepam, topiramate, and levetiracetam(Fig. 1). The treatment received by the patient and the response
in terms of spasm reduction or cessation was noted. The treatment
protocol was modiﬁed if the drugs in next sequence had already
been tried. Treatment response was classiﬁed as spasm cessation
when there was a complete cessation of spasms, partial response
when >50% improvement was observed, and poor response when
there was <50% improvement; two weeks after starting the drug.
2.5. Follow-up records
Records of follow-up were studied to determine the response to
treatment, any evidence of relapse, and progression to other
seizure types. EEG was repeated in patients who developed a
relapse or progressed to have other seizure types and in those with
spasm cessation to document resolution of hypsarrhythmia. An
EEG was also repeated if the patient developed a relapse or
progressed to have other seizure types. The ﬁnal outcome was
considered favorable when there was a complete spasm cessation
for at least 6 months without relapse or progression to other
Table 2
Etiology of West syndrome in the study population.
Etiology Number (%) (N = 148)
Symptomatic (known etiology) 122 (82.4%)
Prenatal causes
Cortical migration defects 5 (4.1%)
Intrauterine infections 2 (1.6%)
Inherited metabolic disorders 2 (1.6%)
Tuberous sclerosis 1 (0.8%)
Perinatal causes
Birth asphyxia 75 (61.4%)
Neonatal sepsis/meningitis 13 (10.6%)
Neonatal hypoglycemia 5 (4.1%)
Prematurity 3 (2.4%)
Perinatal stroke 1 (0.8%)
Postnatal causes
Meningitis/meningoencephalitis 14 (11.4%)
Unknown etiology 26 (17.5%)
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relation to the etiology and clinical variables at presentation.
2.6. Analysis
The data were entered by two investigators (JSK and SS) into
separate Microsoft Excel sheets, the sheets were compared, and
any inconsistency was cross-checked with the original data.
Categorical variables were presented as proportions; their
association with the ﬁnal outcome was compared using the chi-
square test. Continuous variables were presented as mean (SD) and
their associations with the ﬁnal outcome were compared using the
unpaired Student’s t-test. The level of signiﬁcance was assumed at
5%. Multivariate logistic regression was applied keeping the ﬁnal
outcome (favorable outcome) as the dependent variable. Indepen-
dent variables considered in model included; age at onset (in
months), time lag to treatment (in months), gender, history of
neonatal intensive care unit (NICU) stay (yes/no), and etiology. The
statistical analysis was done using SPSS 17.0 version.
3. Results
3.1. Clinical and demographic proﬁle
Records of 148 children were ﬁnally analyzed (records
identiﬁed: 156; excluded for inadequate follow up: 8) (Table 1).
The age at onset of spasms ranged from 1 month to 30 months
[mean 5.3 (4.6) months]. The mean (SD) age at diagnosis of West
syndrome was 13.1 (7.2) months. The mean (SD) lag time to
treatment was 7.9 (7.4) months. There was a male preponderance
[n = 120 (81.1%)] in our study. The median duration of follow-up
was 12 months (range 6–43 months). Developmental delay prior to
the onset of spasms was present in 137 (92.5%) patients. EEG
ﬁndings were compatible with hypsarrhythmia in 63 (42.4%)
children; and with modiﬁed hypsarrythmia in the rest (57.6%).Table 1
Baseline clinical proﬁle of children with West syndrome (N = 148).
Baseline characteristics Values
Mean (SD)
Age at spasm onset in months 5.3 (4.6)
Age at diagnosis in months 13.1 (7.3)
Lead time in months 7.9 (7.4)
Number of clusters per day 12.4 (8.8)
Number of spasms per cluster 4.8 (2.1)
Number (%)
Male gender 120 (81.1%)
Type of spasm
Flexor 113 (76.3%)
Extensor 9 (6.2%)
Mixed 26 (17.6%)
Development prior to spasm onset
Delayed 137 (92.5%)
Normal 11 (7.4%)
Microcephaly 96 (64.9%)
Cerebral palsy 92 (62.2%)
Spastic quadriplegic 82 (55.4%)
Spastic diplegic 8 (5.4%)
Spastic hemiplegic 2 (1.4%)
Comorbidities
Visual impairment 35 (23.6%)
Hearing impairment 15 (10.1%)
Sleep disturbances 9 (6.1%)
Feeding difﬁculties 15 (10.1%)
Recurrent chest infections 7 (4.7%)Almost two-thirds of the children had ﬂexor spasms with the
rest having mixed or extensor spasms. The enrolled children had
an average 10 clusters per day, with each cluster having 5 spasms.
Relationship of spasms with the sleep–wake cycle was observed in
108 (72.9%) children. There were 13 (8.4%) children who were
small for gestational age.
3.2. Etiology
In our study, the majority of the children were symptomatic
[122 (82.4%)]; etiology could not be ascertained in the rest.
Perinatal brain injury was the leading cause of West syndrome,
seen in 81 children (66.3%) (Table 2). Among the perinatal causes,
birth asphyxia was the predominant. Neonatal sepsis/meningitis
(13), neonatal hypoglycemia (5), prematurity (3), kernicterus (1),
and perinatal stroke (1) were the other perinatal etiologies.
Postnatal causes included meningitis and meningoencephalitis in
14 children. Prenatal causes included malformations of cortical
development (5), intrauterine infections (2), tuberous sclerosis (1),
and inherited metabolic disorders (2).
3.3. Treatment response
Drugs used in our study for treatment of children with West
syndrome included pyridoxine (135), prednisolone (122), sodium
valproate (110), vigabatrin (47), nitrazepam (27), topiramate (16),
and levetiracetam (9). The response to treatment is depicted in
Table 3. Complete spasm cessation occurred in only one patient
with pyridoxine. With the use of oral prednisolone, complete
spasm cessation was observed in 31 (25.4%), while an additional
31.9% showed a partial response. Eighteen (16%) children achieved
complete spasm cessation with sodium valproate, and 13 (27.6%)
with vigabatrin. A repeat EEG could be obtained in 65 children with
complete spasm cessation; 19 were normal and hypsarrhythmia
persisted in 12 children. Hypsarrhythmia resolved with presence
of background and other epilepitiform abnormalities in 34
children.
3.4. Factors predicting favorable outcome
Forty-ﬁve children had a favorable outcome. The age at onset,
gender, or lag time for treatment initiation was not found to have
any signiﬁcant role in predicting a favorable outcome (Table 4).
Table 3
Response to treatment among children of West syndrome (N = 148).
Drugs Number tried Spasm cessation Partial response (>50% improvement) No response (<50% improvement)
Pyridoxine 135 (91.2%) 1 (0.7%) 12 (8.9%) 122 (90%)
Prednisolone 122 (82.4%) 31 (25.4%) 39 (32%) 52(42.6%)
Sodium valproate 110 (74.3%) 18 (16.3%) 37 (33.6%) 55 (50%)
Vigabatrin 47 (31.7%) 13 (27.6%) 10 (21.3%) 24 (51.1%)
Nitrazepam 27 (18.2%) 5 (18.5%) 8 (29.6%) 14 (51.8%)
Topiramate 16 (10.8%) 3 (18.8%) 6 (37.5%) 7 (43.7%)
Levetiracetam 9 (6.1%) 0 5 (55.5%) 4(44.4%)
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children in whom no underlying etiology could be found (P = 0.05).
Multivariate logistic regression revealed that male gender [OR
1.377 (95% CI 0.562–3.372) (P = 0.484)], history of NICU stay [OR
1.06 (95% CI 0.495–2.295) (P = 0.871)], symptomatic etiology [OR
1.866 (95% CI 0.728–4.888) (P = 0.192)], age at onset [OR 0.994
(95% CI 0.917–1.076) (P = 0.873)] and time lag to treatment [OR
1.033 (95% CI 0.976–1.093) (P = 0.265)] did not affect the ﬁnal
outcome.
4. Discussion
This was a large retrospective study of children with West
syndrome conducted in resource-constrained settings of a
developing country. We observed that symptomatic West syn-
drome formed a major group (82%) and that was signiﬁcantly
associated with an unfavorable outcome. Age at onset, etiology,
and lag time in treatment did not effect the ﬁnal outcome. Our
study highlights the clinical spectrum, treatment response, and
predictors of outcome in children with West syndrome, hence
providing a developing country perspective. The challenges faced
in our setting include delayed presentation; inability for patients to
procure expensive medications like ACTH, vigabatrin, and levetir-
acetam; and difﬁculty in admitting the patient to the inpatient
setting for ACTH treatment owing to overcrowding in the hospital
and the risk of developing cross infections.
The mean age at onset of infantile spasms (5.3 months) was
comparable to experience at other centers.8–10 Mean lag time in
treatment initiation in most of the Western studies varies between
25 and 45 days.8–10 The lag time was signiﬁcantly higher in our
study, likely owing to the health-seeking behavior of parents; lack
of awareness on this ailment among the pediatricians; and use of
inappropriate antiepileptics such as phenobarbitone, phenytoin,
and carbamazepine. These are acknowledged as lacunae in the
treatment of children in the developing countries.3,4 Surprisingly,
we did not ﬁnd any association of the lag time with the ﬁnal
outcome. This is in contrast to earlier studies, that demonstrated
better long term outcome in children with early treatment
inititation.6,11 Improving awareness of clinicians and parents
about infantile spasms and helping them differentiate it fromTable 4
Factors affecting the ﬁnal outcome.
Factors Favorable outcome (N = 45) 
Mean (SD)
Age at onset (months) 5.6 (5.3) 
Time lag (months) 6.9 (5.7) 
Proportions
Male gender 35 (77.8%) 
Birth asphyxia 22 (48.9%) 
NICU stay 20 (44.4%) 
Neonatal sepsis 9 (20%) 
Spastic quadriplegia 24 (53.3%) 
Microcephaly 27 (60%) 
Symptomatic etiology 34 (75.6%) abdominal colic or startle reﬂex might reduce the lag time. We
acknowledge that the relatively small sample size of our study
could also probably inﬂuence the impact of lag time to treatment
on the ﬁnal outcome.
We found a striking male preponderance in our study, probably
owing to gender-biased referral and treatment-seeking behavior of
parents. This gender bias is well rooted in the traditional culture of
the Indian society where male children are brought to medical
attention more frequently and females are neglected. These
ﬁndings are similar to other studies from the Indian subconti-
nent.3,4 We observed that 92.5% of children had developmental
delay preceding the onset of spasms. In our study, almost two-
thirds of children were microcephalic and half had comorbid
spastic quadriplegic cerebral palsy. These ﬁndings are consistent
with previous reports.3,4,12 However, we did not observe the effect
of these parameters on the ﬁnal outcome. High rates of
comorbidities such as cerebral palsy, microcephaly, vision and
hearing impairment, and feeding difﬁculties as sequelae of
perinatal insults are additional problems in children with West
syndrome in our scenario.
The proportion of symptomatic cases is higher in our scenario as
compared to Western data. In the United Kingdom infantile spasms
study, a known etiology could be demonstrated in 61% of the cases,
whereas in our study, 82% of the patients had a known etiology.13
The etiological proﬁle in our study was also considerably different
from the West. The most common cause of was a perinatal brain
injury, especially perinatal asphyxia. In contrast, prenatal causes
which include cortical malformations, neurocutaneous syndromes,
and genetic–metabolic disorders are the predominant etiologies in
the West.13–15 High incidence of perinatal asphyxia in our study
setting could be attributed to lack of antenatal care, high rates of
home delivery, delivery by unskilled workers, delay in treatment
initiation, and a poor referral system. Improvement in the maternal
and neonatal health services may help in reducing the incidence of
West syndrome in developing countries.
We found a spasm cessation rate of 25.4% with oral predniso-
lone. In the doses used (2 mg/kg/day), oral prednisolone has been
shown to be less effective as compared to ACTH. Spasm freedom
rates ranging from 25% to 33% have been found at this dose,
compared to 70% response rate with ACTH.16–18 Our response ratesUnfavorable outcome (N = 103) P value
5.2 (4.2) 0.65
8.3 (7.9) 0.29
85 (82.5%) 0.50
55 (53.4%) 0.61
53 (51.5%) 0.43
23 (22.3%) 0.75
58 (56.3%) 0.89
69 (67%) 0.41
88 (85.4%) 0.05
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problem of delayed presentation which may have also reduced the
responder rates. Recent data suggest that the use of high-dose
prednisolone (40–60 mg/day) may be as effective as ACTH.19,20 In
the United Kingdom infantile spasms study, spasm freedom was
achieved in 70% of children taking high-dose oral prednisolone
(40 mg/day) and 76% of children taking ACTH (40 IU/alternate
day).19 The risks of using the high-dose steroid in developing
countries like India, especially infections, have to be balanced with
the advantages. A randomized trial comparing the usual dose
(2 mg/kg/day) and high dose (4 mg/kg/day) in children with newly
diagnosed West syndrome is now in progress at our center (Clinical
Trials.Gov identiﬁer NCT01575639).
As vigabatrin is expensive, it was offered only to those patients
who failed steroids and were able to afford it. In our study, out of 47
such patients, 13 had spasm freedom accounting to the responder
rate of 27.6%. This is lower than the 54% response rate reported in the
literature,19 but this is likely due to the delay in treatment initiation
and use as a second-line agent. Other drugs such as sodium
valproate, topiramate, and nitrazepam showed modest efﬁcacy
ranging from 16% to 19%, which is lower than previous reported
literature,21–23 but could be accounted for by the fact that these
drugs were used as second- and third-line agents, which might have
resulted in reduced efﬁcacy. Pyridoxine was also not found to be a
useful agent, contrary to reports from Japan, where this agent has
been used extensively for the treatment of infantile spasms.24 Only
one child in our cohort was pyridoxine responsive. Hence, we
consider that the pyridoxine drug trial may not be warranted in our
setting. Perhaps the response may improve with higher doses or the
use of other formulations such as pyridoxal phosphate.25
In our study, we preferred the term ‘‘favorable outcome’’
instead of treatment success and treatment failure, considering
that EEG evidence of hypsarrhythmia might persist despite
cessation of clinical spasms. Deﬁnition of favorable outcome
was more clinically relevant and parent-centered.
The limitations of the study include the absence of long-term
video-EEG monitoring for assessing treatment outcomes and lack
of long-term follow-up. Lack of long-term follow-up is difﬁcult in
our study setting owing to the large proportion children who
belong to the migrant population in Delhi. Also, we did not
objectively assess the developmental outcome. Another limitation
to be considered while assessing treatment outcomes is that the
natural history of spasms must be taken into account, with the
possibility of spontaneous remission. This is all the more important
in our scenario with delayed presentation. However, despite these
shortcomings, the data of this large number of patients gives us an
insight into the challenges faced in the management of West
syndrome in resource constrained settings.
In conclusion, we describe the clinico-etiological proﬁle and
treatment outcome of children with West syndrome in a developing
country scenario. The commonest etiology was perinatal brain
injury, especially birth asphyxia. There was a prolonged lag time
between the onset of spasms and initiation of treatment. Symptom-
atic etiology was associated with an unfavorable outcome.
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